Latest On Zealand Pharma A/S (ZLDPF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 14:46 EST | News | Zealand Pharma reports Q1 results | N/A |  |
| 2023-05-11 14:46 EST | News | Zealand Pharma A/S (ZEAL) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-10 11:11 EST | News | Boehringer, Zealand's drug helps cut weight up to 14.9%, meets phase 2 trial's goal | N/A | |
| 2023-03-13 08:20 EST | News | Zealand Pharma expects recovery of DKK 162.6M from Silicon Valley Bank | N/A | |
| 2023-03-03 02:21 EST | News | Zealand Pharma A/S (ZEAL) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-02 11:31 EST | News | Zealand Pharma GAAP EPS of -DKK 20.90, revenue of DKK 104M | N/A | |
| 2022-11-11 22:58 EST | News | Zealand Pharma A/S (ZEAL) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-08-11 20:59 EST | News | Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-06-02 19:47 EST | News | Dr. David Kendall named Zealand Pharma CMO | N/A | |
| 2022-05-13 05:27 EST | News | Zealand Pharma A/S (ZEAL) CEO Adam Steensberg on Q1 2022 Earnings Call Transcript | N/A | |
| 2022-05-10 20:32 EST | News | Zealand Pharma amends existing financing agreement with Oberland Capital | N/A | |
| 2022-04-13 12:14 EST | News | Zealand Pharma (ZEAL) Investor Presentation - Slideshow | N/A | |
| 2022-03-11 05:12 EST | News | Zealand Pharma A/S 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-11 05:12 EST | News | Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-11 18:59 EST | News | Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-13 06:29 EST | News | Zealand Pharma A/S 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-08-13 06:29 EST | News | Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-03-18 19:09 EST | Analyst Rating | The Analyst Target Price has decreased from $220.24 to $35.25. | Sell | |
| 2021-03-18 07:19 EST | Analyst Rating | The Analyst Target Price has increased from $35.32 to $220.24. | Buy | |
| 2021-03-17 15:18 EST | Analyst Rating | The Analyst Target Price has decreased from $35.38 to $35.32. | Sell | |
| 2021-03-17 07:17 EST | Analyst Rating | The Analyst Target Price has decreased from $35.39 to $35.38. | Sell | |
| 2021-03-16 23:46 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-16 23:46 EST | Analyst Rating | The Analyst Target Price has decreased from $36.16 to $35.39. | Sell | |
| 2021-03-13 05:47 EST | Analyst Rating | The Analyst Target Price has increased from $35.98 to $36.16. | Buy | |
| 2021-03-12 17:36 EST | Analyst Rating | The Analyst Target Price has decreased from $221.88 to $35.98. | Neutral | |
| 2021-03-12 06:10 EST | Analyst Rating | The Analyst Target Price has increased from $35.49 to $221.88. | Buy | |
| 2021-03-11 20:35 EST | News | Zealand Pharma A/S 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-03-11 20:35 EST | News | Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-11 17:41 EST | Analyst Rating | The Analyst Target Price has decreased from $221.88 to $35.49. | Sell | |
| 2021-03-11 05:52 EST | Analyst Rating | The Analyst Target Price has increased from $35.35 to $221.88. | Buy | |
| 2021-03-10 17:36 EST | Analyst Rating | The Analyst Target Price has decreased from $221.88 to $35.35. | Sell | |
| 2021-03-10 06:27 EST | Analyst Rating | The Analyst Target Price has increased from $35.58 to $221.88. | Buy | |
| 2021-03-09 05:58 EST | Analyst Rating | The Analyst Target Price has decreased from $35.69 to $35.58. | Sell | |
| 2021-03-06 02:07 EST | Analyst Rating | The Analyst Target Price has decreased from $35.94 to $35.69. | Neutral | |
| 2021-03-05 17:41 EST | Analyst Rating | The Analyst Target Price has increased from $35.63 to $35.94. | Buy | |
| 2021-03-05 09:53 EST | Analyst Rating | The Analyst Target Price has decreased from $35.75 to $35.63. | Neutral | |
| 2021-03-04 17:42 EST | Analyst Rating | The Analyst Target Price has decreased from $219.98 to $35.75. | Neutral | |
| 2021-03-04 05:54 EST | Analyst Rating | The Analyst Target Price has increased from $35.64 to $219.98. | Buy | |
| 2021-03-03 17:44 EST | Analyst Rating | The Analyst Target Price has decreased from $219.98 to $35.64. | Neutral | |
| 2021-03-03 09:58 EST | Analyst Rating | The Analyst Target Price has increased from $35.76 to $219.98. | Buy | |
| 2021-03-02 17:41 EST | Analyst Rating | The Analyst Target Price has decreased from $219.98 to $35.76. | Neutral | |
| 2021-03-02 02:32 EST | Analyst Rating | The Analyst Target Price has increased from $35.97 to $219.98. | Buy | |
| 2021-03-01 17:40 EST | Analyst Rating | The Analyst Target Price has decreased from $219.98 to $35.97. | Neutral | |
| 2021-02-27 05:49 EST | Analyst Rating | The Analyst Target Price has increased from $36 to $219.98. | Buy | |
| 2021-02-26 22:20 EST | Analyst Rating | The Analyst Target Price has decreased from $222.35 to $36. | Neutral | |
| 2021-02-26 06:04 EST | Analyst Rating | The Analyst Target Price has increased from $36.33 to $222.35. | Buy | |
| 2021-02-25 17:38 EST | Analyst Rating | The Analyst Target Price has decreased from $222.35 to $36.33. | Neutral | |
| 2021-02-25 06:40 EST | Analyst Rating | The Analyst Target Price has increased from $36.37 to $222.35. | Buy | |
| 2021-02-24 17:48 EST | Analyst Rating | The Analyst Target Price has decreased from $222.35 to $36.37. | Neutral | |
| 2021-02-24 06:26 EST | Analyst Rating | The Analyst Target Price has increased from $36.25 to $222.35. | Buy | |
About Zealand Pharma A/S (ZLDPF):
Zealand Pharma A/S, a biotechnology company, engages in the discovery and development of peptide-based medicines in Denmark. It has a portfolio of medicines in development stage focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes glepaglutide, a long acting GLP-2 analog, which is in Phase 3 clinical trials for the treatment of short bowel syndrome; and dasiglucagon, a stable glucagon analog for the treatment of severe hypoglycemia in diabetes and congenital hyperinsulinism, as well as for use in dual-hormone artificial pancreas for automated diabetes management. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; and Beta Bionics, Inc. to initiate home-use trial of the iLet bionic pancreas with dasiglucagon for autonomous bihormonal treatment of type 1 diabetes, as well as research agreement with Orbit Discovery Ltd. and Torrey Pines Institute for Molecular Studies. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
General
- Name Zealand Pharma A/S
- Symbol ZLDPF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 329
- Fiscal Year EndDecember
- Web URLhttp://www.zealandpharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 21.43
- Price/Book (Most Recent Quarter) 7.27
- Enterprise Value Revenue 3.26
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -240%
- Return on Assets -30%
- Return on Equity -69%
- Revenue Per Share $0
- Gross Profit 262.75 million
- Quarterly Earnings Growth 451.3%
Highlights
- Market Capitalization 1.32 billion
- Analyst Target Price $35.25
Share Statistics
- Shares Outstanding 43.34 million
- Shares Float 30.68 million
- % Held by Insiders 10%
- % Held by Institutions 58.65%
Technicals
- Beta 0.94
- 52 Week High $42.3
- 52 Week Low $24.6
- 50 Day Moving Average 32.98
- 200 Day Moving Average 35.91
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Zealand Pharma A/S (ZLDPF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Zealand Pharma A/S (ZLDPF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | -$1.53 | ||
| 2020-09-30 | 2020-11-12 | $N/A | -$5.76 | ||
| 2020-06-30 | 2020-09-30 | $N/A | -$0.91 | ||
| 2020-03-31 | 2020-06-30 | $12.42 million | -$0.24 | ||
| 2019-12-31 | 2020-03-31 | $11.49 million | -$0.74 | ||
| 2019-09-30 | 2019-12-31 | $9.92 million | -$0.80 | ||
| 2019-06-30 | 2019-09-30 | $19.92 million | -$0.50 | ||
| 2019-03-31 | 2019-06-30 | $N/A | -$0.66 | ||
| 2018-12-31 | 2019-03-31 | $2.01 million | -$0.62 | ||
| 2018-09-30 | 2018-12-31 | $N/A | -$0.65 | ||
| 2018-06-30 | 2018-09-30 | $2.36 million | $4.66 | ||
| 2018-03-31 | 2018-06-30 | $1.61 million | -$0.56 | ||
| 2017-12-31 | 2018-03-31 | $1.82 million | -$0.52 | ||
| 2017-09-30 | 2017-12-31 | $6.32 million | -$0.56 | -$2.23 | 75.03% |
| 2017-06-30 | 2017-09-30 | -$0.24 | |||
| 2017-03-31 | 2017-06-30 | -$0.57 | -$0.90 | 37.02% | |
| 2016-12-31 | 2017-03-31 | -$0.15 | |||
| 2016-09-30 | 2016-12-31 | $0.29 | $0.45 | -35.04% | |
| 2016-06-30 | 2016-09-30 | -$0.19 | -$3.52 | 94.47% | |
| 2016-03-31 | 2016-06-30 | -$0.61 | -$2.96 | 79.32% | |
| 2015-12-31 | 2016-03-31 | -$0.50 | $4.21 | -111.88% | |
| 2015-09-30 | 2015-12-31 | $0.41 | -$2.36 | 117.39% | |
| 2015-06-30 | 2015-09-30 | -$0.33 | -$1.76 | 81.21% | |
| 2015-03-31 | 2015-06-30 | -$0.51 | -$2.00 | 74.62% | |
| 2014-12-31 | 2015-03-31 | -$0.34 | -$2.70 | 87.33% | |
| 2014-09-30 | 2014-12-31 | -$0.43 | -$0.40 | -7.28% | |
| 2014-06-30 | 2014-09-30 | $0.13 | -$2.00 | 106.28% | |
| 2014-03-31 | 2014-06-30 | -$0.39 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.23 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.36 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.28 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.36 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.43 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.41 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.01 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.18 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.52 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.15 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.12 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.79 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.26 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.53 | $0.00 |
Zealand Pharma A/S (ZLDPF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Zealand Pharma A/S (ZLDPF) Chart:
Zealand Pharma A/S (ZLDPF) News:
Below you will find a list of latest news for Zealand Pharma A/S (ZLDPF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Zealand Pharma A/S (ZLDPF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Zealand Pharma A/S (ZLDPF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|